ArticleOncology letters2026
Logistic regression analysis of risk factors for abdominal adhesion during hyperthermic intraperitoneal chemotherapy for ovarian cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to explore the risk factors for abdominal adhesion during hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer via logistic regression analysis. The present study is a retrospective analysis involving 165 patients with ovarian cancer treated at The Department of Gynecology, Shanghai First Maternity and Infant Hospital (Shanghai, China) from February 2021 to June 2023. All patients were treated with HIPEC or adjuvant therapy. During the treatment, the patients were divided into the control (n=61) and observation (n=104) groups according to the presence of abdominal adhesion. The results of the present study highlighted the notable role of monitoring biomarkers such as C-reactive protein and plasminogen activator inhibitor-1 in predicting the risk of abdominal adhesions in patients with ovarian cancer treated with HIPEC. By optimizing surgical techniques, controlling inflammatory reactions, adopting anti-adhesion strategies and implementing detailed preoperative assessment and preventive measures for patients undergoing HIPEC, the incidence of adhesions may be effectively reduced and treatment safety improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.